Most PAH patients who completed one year in a CS1 expanded access program had stable or improved clinical measures.

A study linked elevated blood levels of uric acid, a metabolic breakdown product often associated with gout, to a higher risk ...

Reflecting on this year's PHA conference in Dallas, columnist Mike Naple writes that connecting with community can be the ...

Blocking a signaling pathway in certain white blood cells may prevent clots from obstructing blood flow and causing CTEPH, per a new study.

Although there is no cure yet for pulmonary hypertension (PH), there are a variety of therapies available that can help manage the symptoms of the disease and maintain or improve the quality of life ...

Treatment with mosliciguat, an inhaled medication given once-daily for pulmonary hypertension (PH), can safely reduce the resistance against blood flow in blood vessels of the lungs, according to a ...

Pulmonary hypertension (PH) is a rare but life-threatening disease that affects the pulmonary arteries, making them narrow and thick. The vessels, which are responsible for transporting blood from the ...

An early feasibility study evaluating Third Pole Therapeutics‘ eNOfit — a miniaturized, portable inhaled nitric oxide (iNO) delivery system to treat pulmonary hypertension (PH) associated with ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google A clinical trial testing mosliciguat, an inhaled therapy for ...

Raymond Benza, MD, has been selected to be director of pulmonary hypertension (PH) for the Mount Sinai Health System, In this newly created position, Benza will seek to advance and standardize care ...

The Pulmonary Hypertension Association (PHA) has launched a certificate program to provide advanced practice providers and allied health professionals with specialized training for diagnosis, ...